CJC-1295 – With DAC (5mg)

What is CJC-1295 – With DAC (5 mg)?

CJC-1295 – With DAC (5 mg) is a synthetic growth hormone–releasing hormone (GHRH) analog used in laboratory research to study growth hormone signaling and broader endocrine communication in models. This peptide includes a Drug Affinity Complex (DAC), which enhances its stability and prolongs its persistence in experimental systems. The DAC modification allows it to remain engaged with receptors longer, making it distinct from non-DAC versions.

The DAC modification enables researchers to study how extended peptides influence receptor engagement and signaling pathways over time. This feature is particularly useful in experiments comparing short-acting and long-acting peptide variants.

Product Specifications

• Category: Peptides
• Subcategory: Muscle Growth & Performance Peptides
• CAS Number: 863288-34-0
• Peptide Sequence:
  Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3647.2 g/mol
• Purity: ≥ 95% (verified using standard analytical methods)
• Packaging Format: Lyophilized powder, 5 mg vial
• Storage Conditions: Store at 2–8 °C (≤ –20 °C for long-term storage). Protect from light.
• Intended Use: For laboratory research use only

Key Characteristics of CJC-1295 – With DAC (5 mg)

• Synthetic peptide designed for consistent research outcomes and reproducibility.
• The DAC modification enables albumin binding in models, supporting extended peptide stability.
• Suitable for studies examining sustained peptide activity and receptor engagement.
• Supplied as a freeze-dried powder to preserve structural integrity during storage.
• Verified using standard testing methods: HPLC and mass spectrometry.
• Compatible with standard peptide handling and cold storage procedures.
• For laboratory research only; not intended for medical, therapeutic, or diagnostic use.

How CJC-1295 – With DAC (5 mg) Supports Research

CJC-1295 – With DAC (5 mg) is used in laboratory studies to explore peptide-driven endocrine signaling related to growth hormone regulation. The DAC modification enables prolonged receptor engagement and extended peptide activity, allowing researchers to observe intracellular signaling patterns in controlled experimental systems.

The DAC modification makes this peptide especially valuable in experiments comparing short-acting and long-acting peptide variants. The focus is on understanding the biological processes, not clinical treatments.

Research Applications & Usage Information

CJC-1295 – With DAC (5 mg) is commonly used in the following types of laboratory research:

• Growth hormone signaling studies: Research on how growth hormone pathways work in models.
• Peptide–receptor interaction: Studies on how peptides bind to receptors and trigger signaling.
• Comparative research: Research comparing short-acting and long-acting peptides.
• Endocrine communication models: Studies on hormone regulation and signaling in cell cultures or animal models.
• Peptide stability studies: Research comparing the lasting effects of extended peptides versus short-acting ones.

Handling and Storage Recommendations

• Store unopened vials at –20 °C for long-term stability.
• Protect from light, heat, and moisture to maintain peptide quality.
• Let the vial reach room temperature before reconstitution to prevent condensation.
• After reconstitution, store solutions at 2–8 °C per lab protocol.
• Minimize freeze–thaw cycles to prevent degradation.
• Follow standard laboratory safety protocols for handling peptides.
• Dispose of materials according to local regulations.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
2. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
4. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536